Protected L-Alanine Derivatives for Stable Opioid Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid receptor modulators, such as morphine, face challenges with instability and adverse side effects, limiting their therapeutic efficacy and safety for conditions like pain and gastrointestinal disorders.
Innovation Solution
A novel process for preparing protected L-alanine derivatives, which are intermediates in the synthesis of mu/delta opioid modulators, involves reacting a compound with zinc in the presence of iodine and a palladium catalyst, followed by oxidation, to produce compounds like (S)-2-tert-butoxycarbonylamino-3-(4-cyano-2,6-dimethylphenyl)-propionic acid methyl ester or its pharmaceutically acceptable salt.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current opioid receptor modulators like morphine are used, then analgesic activity is achieved, but stability is poor and adverse side effects occur
Solution Approach 1:
The patent segments the opioid receptor modulator into distinct components: a stabilized core structure (compounds of formula I) and separate functional groups. The core structure is designed to maintain stability while functional groups provide the necessary opioid activity, allowing the molecule to achieve both reliability and reduced side effects through modular design.
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure of opioid modulators through specific substitutions at defined positions (R1-R6 groups) to optimize the balance between stability and side effect profile. By systematically varying these parameters, the patent identifies structures that maintain analgesic activity while improving stability and reducing adverse effects.
2Device complexity
If truncated dipeptide structures are used to simplify enkephalins, then opioid activity is maintained, but inherent instability increases
Solution Approach 1:
The patent segments the truncated dipeptide structure into a stable core framework with defined substitution patterns. By dividing the molecule into functional segments (R1-R6 groups at specific positions), the patent maintains the simplified structure for low complexity while the core framework provides enhanced stability compared to traditional truncated dipeptides.
Solution Approach 2:
The patent creates a composite molecular structure combining a stable core scaffold with various functional groups (R1-R6) that can be independently optimized. This composite approach allows the molecule to benefit from both the simplicity of truncated dipeptides and the stability of a robust core structure, resolving the contradiction between complexity and stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process yields substantially pure compounds that can serve as effective intermediates for opioid receptor modulators, potentially offering improved stability and reduced side effects, enhancing their medicinal utility for pain and gastrointestinal disorders.
Implementation Method 1
reacting a compound of formula (X-B) with zinc; in the presence of a source of iodine; in a first organic solvent or mixture a mixture of organic solvents, wherein the first organic solvent is non-reactive to the source iodine; to yield the corresponding compound of formula (XI-B)
Implementation Method 2
reacting the compound of formula (XI-B) with a compound of formula (XII-B); in the presence of a palladium catalyst and phosphine ligand system; in a second organic solvent or a mixture of organic solvents; to yield the corresponding compound of formula (I-B)
Implementation Method 3
reacting said compound of formula (I-B) with an oxidizing agent; in the presence of an inorganic base; in a third organic solvent; to yield the corresponding compound of formula (II-B)
Data Source
AI summary
The present invention is directed to a novel process for the preparation of protected L-alanine derivatives, useful as intermediates in the synthesis of compounds useful as mu/delta opioid modulators.